Article info
Review
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
- Correspondence to Dr Kevin L Winthrop, Division of Infectious Diseases, Oregon Health and Science University, 3375 SW Terwilliger Blvd, Portland, OR 97239, USA; Winthrop{at}ohsu.edu
Citation
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
Publication history
- Received April 24, 2015
- Revised July 31, 2015
- Accepted August 28, 2015
- First published September 22, 2015.
Online issue publication
March 02, 2022
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/